Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts 122
Year : 2017  |  Volume : 8  |  Issue : 2  |  Page : 65-67

Crizotinib in treatment of lung cancer

1 Department of Pharmacology, Government Medical College, Kannauj, Uttar Pradesh, India
2 Department of Respiratory Medicine, King George's Medical University, Lucknow, Uttar Pradesh, India
3 Department of Respiratory Medicine, Command Hospital (Central Command), Lucknow, Uttar Pradesh, India

Correspondence Address:
Surya Kant
Department of Respiratory Medicine, King George's Medical University, Chowk, Lucknow - 226 003, Uttar Pradesh
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/mjmsr.MJMSR_62_16

Rights and Permissions

Lung cancer is one of the most common malignancies and is the leading cause of cancer-related mortality throughout the world. Despite advances in surgery and chemotherapy, survival is still poor. Crizotinib is an oral inhibitor of multiple kinases, including anaplastic lymphoma kinase (ALK), and is indicated in the treatment of patients with locally advanced or metastatic? non small cell lung carcinoma (NSCLC) harboring ALK mutation as a targeted therapy. This is short drug review of crizotinib in the treatment of advanced lung cancer.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded1290    
    Comments [Add]    

Recommend this journal